HRES253-119

In Committee

Expressing support for the designation of May 15, 2025, as "Prader-Willi Syndrome Awareness Day" to raise awareness of and promote research on the disorder.

119th Congress Introduced Mar 25, 2025

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

This is a simple House resolution that expresses Congress's support for designating May 15, 2025 as "Prader-Willi Syndrome Awareness Day." Prader-Willi syndrome is a rare genetic disorder that affects approximately 1 in 15,000 people. The resolution recognizes the efforts of advocacy groups and calls attention to the need for better awareness, early diagnosis, research, and treatment development. Importantly, this is a non-binding resolution - it does not create any new laws, funding, or requirements.

Who Benefits and How

Prader-Willi syndrome patients, their families, and advocacy organizations receive symbolic recognition and congressional support. This may help raise public awareness and could potentially pave the way for future legislation that provides actual funding or regulatory changes. However, the resolution itself provides no tangible benefits such as research funding, insurance coverage mandates, or treatment subsidies. Medical researchers and pharmaceutical companies working on rare disease treatments receive acknowledgment that regulatory pathways for drug development are important, but no concrete policy changes.

Who Bears the Burden and How

No one bears any burden from this resolution. It requires no action from any federal agency, imposes no new regulations on businesses, and allocates no taxpayer funds. There are no compliance requirements, reporting mandates, or other obligations created by this resolution.

Key Provisions

  • Supports the designation of May 15, 2025 as Prader-Willi Syndrome Awareness Day
  • Applauds advocacy organizations and individuals working to support people affected by the disorder
  • Recognizes the commitment of parents, families, researchers, and health professionals seeking treatments and cures
  • Emphasizes the importance of public awareness, early and accurate diagnosis, advancing research, developing new treatments, and identifying regulatory pathways for rare disease drug development
  • Creates no funding, mandates, or regulatory changes (purely symbolic expression of congressional support)

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.

At a Glance

What This Bill Does

A non-binding resolution expressing support for designating May 15, 2025 as Prader-Willi Syndrome Awareness Day and promoting awareness and research for this rare genetic disorder.

Who Benefits

  • Prader-Willi syndrome patients and families
  • Rare disease advocacy organizations
  • Medical researchers focused on genetic disorders

Key Policy Areas

Healthcare, Rare Diseases, Medical Research, Public Health Awareness

Primary Purpose

A non-binding resolution expressing support for designating May 15, 2025 as Prader-Willi Syndrome Awareness Day and promoting awareness and research for this rare genetic disorder.

Policy Domains

Healthcare Rare Diseases Medical Research Public Health Awareness

Legislative Strategy

"Non-binding symbolic resolution to raise awareness for a rare genetic disorder affecting approximately 1 in 15,000 births"

Identified Gains

  • Prader-Willi syndrome patients and families
  • Rare disease advocacy organizations
  • Medical researchers focused on genetic disorders
  • Healthcare professionals treating rare diseases

Legislative Progress

In Committee
Introduced Committee Passed
Mar 25, 2025

Mr. Tonko (for himself and Ms. Salazar) submitted the following …

Mar 25, 2025

Referred to the House Committee on Energy and Commerce.

Mar 25, 2025

Submitted in House

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Healthcare
1 mention across 1 clause
?1 uncertain

Prader-Willi syndrome advocacy organizations and patient support groups

Research & Science
1 mention across 1 clause
?1 uncertain

Rare disease researchers and pharmaceutical companies developing Prader-Willi syndrome treatments

Healthcare Beneficiaries
1 mention across 1 clause
?1 uncertain

Patients and families affected by Prader-Willi syndrome

1/1
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Rare Diseases Medical Research

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology